Recommendation for the Management of Spondyloarthritis Patients in Kuwait

References

• Proft F, Poddubnyy D. Ankylosing spondylitis and axial spondyloarthritis: recent insights and impact of new classification criteria. Ther Adv Musculoskel Dis. 2018;10(5–6):129–139. doi:10.1177/1759720X18773726
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Ramiro S, Landewé R, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978–991. doi:10.1136/annrheumdis-2016-21077028087505
   PubMed Web of Science ®Google Scholar
• van Tubergen A. The changing clinical picture and epidemiology of spondyloarthritis. Nat Rev Rheumatol. 2015;11(2):110–118. doi:10.1038/nrrheum.2014.18125385414
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68(6):777–783. doi:10.1136/ard.2009.10823319297344
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31. doi:10.1136/ard.2010.13364521109520
   PubMed Web of Science ®Google Scholar
• Smolen JS, Braun J, Dougados M, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16. doi:10.1136/annrheumdis-2013-20341923749611
   PubMed Web of Science ®Google Scholar
• Paramarta JE, Baeten D. Spondyloarthritis: from unifying concepts to improved treatment. Rheumatology. 2014;53(9):1547–1559. doi:10.1093/rheumatology/ket40724369419
   PubMed Web of Science ®Google Scholar
• Pfizer. Press release. [Internet. Accessed 813, 2018]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_provides_update_on_global_regulatory_approvals_and_launches_of_xeljanz_tofacitinib_citrate_for_the_treatment_of_rheumatoid_arthritis.
   Google Scholar
• Pfizer. Press release. [Internet]. 2018 Available from: https://press.pfizer.com/press-release/pfizer-announces-fda-approval-xeljanz-tofacitinib-and-xeljanz-xr-treatment-active-psor.
   Google Scholar
• European Medicines Agency. Summary of opinion. Xeljanz. Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/004214/WC500247974.pdf. Accessed 7 2018
   Google Scholar
• Xeljanz® (tofacitinib) Summary of Product Characteristics (Gulf Levant), Pfizer; 2019
   Google Scholar
• Ward MM, Deodhar A, Akl EA, et al. American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arth Rheumatol. 2016;68:282–298. doi:10.1002/art.3929826401991
   PubMed Web of Science ®Google Scholar
• Rohekar S, Chan J, Tse SM, et al. 2014 Update of the Canadian Rheumatology Association/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis. Part I: principles of the management of spondyloarthritis in Canada. J Rheumatol. 2015;42:654–664. doi:10.3899/jrheum.14100025684770
   PubMed Web of Science ®Google Scholar
• Hammoudeh M, Abdulaziz S, Alosaimi H, et al. Challenges of diagnosis and management of axial spondyloarthritis in North Africa and the Middle East: an expert consensus. J Int Med Res. 2016;44(2):216–230. doi:10.1177/030006051561153626811411
   PubMed Web of Science ®Google Scholar
• Al Enizi A, AlSaeid K, Alawadhi A, et al. Kuwait recommendations on vaccine use in people with inflammatory rheumatic disease. Int J Rheumatol. 2018;5217461.29861734
   PubMed Web of Science ®Google Scholar
• AL-Herz A, Saleh K, Al-Awadhi A, et al. Easy accessibility of biologics and its impact on disease activity and quality of life in Kuwaiti patients with rheumatoid arthritis [abstract]. Arthritis Rheumatol. 2018;70(suppl):10.
   Google Scholar
• Al Emadi S, Hammoudeh M, Mounir M, Mueller RB, Wells AF, Sarakbi HA. An assessment of the current treatment landscape for rheumatology patients in Qatar: recognising unmet needs and moving towards solutions. J Int Med Res. 2017;45(2):733–743. doi:10.1177/030006051668687228415924
   PubMed Web of Science ®Google Scholar
• World population review. Available from: http://worldpopulationreview.com/countries/kuwait-population/. Accessed 138 2018.
   Google Scholar
• Alawadhi A, Olusi SO, Al-Saeid K, et al. Incidence of musculoskeletal pain in adult Kuwaitis using the validated Arabic version of the WHO-ILAR COPCORD Core Questionnaire. Ann Saudi Med. 2005;25(6):459–462. doi:10.5144/0256-4947.2005.45916438453
   PubMed Web of Science ®Google Scholar
• Oswald AE, Bell MJ, Snell L, et al. The current state of musculoskeletal clinical skills teaching for preclerkship medical students. J Rheumatol. 2008;35(12):1384. doi:10.3899/jrheum.08030818464299
   PubMed Web of Science ®Google Scholar
• Landewé R, van Tubergen A. Clinical tools to assess and monitor spondyloarthritis. Curr Rheumatol Rep. 2015;17(7):47. doi:10.1007/s11926-015-0522-326063534
   PubMed Web of Science ®Google Scholar
• Machado P, Landewé R, Lie E, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47–53. doi:10.1136/ard.2010.13859421068095
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3–17. doi:10.1136/annrheumdis-2017-21173428684559
   PubMed Web of Science ®Google Scholar
• Ramiro S, van der Heijde D, van Tubergen A, et al. Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort. Ann Rheum Dis. 2014;73(8):1455–1461. doi:10.1136/annrheumdis-2014-20517824812292
   PubMed Web of Science ®Google Scholar
• Poddubnyy D, Protopopov M, Haibel H, Braun J, Rudwaleit M, Sieper J. High disease activity according to the Ankylosing Spondylitis Disease Activity Score is associated with accelerated radiographic spinal progression in patients with early axial spondyloarthritis: results from the GErman SPondyloarthritis Inception Cohort. Ann Rheum Dis. 2016;75(12):2114–2118. doi:10.1136/annrheumdis-2016-20920927125522
   PubMed Web of Science ®Google Scholar
• Pereira IA, Neves FS, Castro GRW. Extra-articular manifestations in spondyloarthritis are common and should be screened. Rheumatol Curr Res. 2012;2:3.
   Google Scholar
• Gupta N, Agarwal A. Management of uveitis in spondyloarthropathy: current trends. Perm J. 2018;22:17–041.
   Google Scholar
• Przepiera-Będzak H, Fischer K, Brzosko M. Extra-articular symptoms in constellation with selected serum cytokines and disease activity in spondyloarthritis. Mediators Inflamma. 2016;7617954.
   Web of Science ®Google Scholar
• Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis. 2009;68(Suppl 2):ii1–44. doi:10.1136/ard.2008.10401819433414
   PubMed Web of Science ®Google Scholar
• Essers I, Boonen A, Busch M, et al. Fluctuations in patient reported disease activity, pain and global being in patients with ankylosing spondylitis. Rheumatology (Oxford). 2016;55(11):2014–2022. doi:10.1093/rheumatology/kew30327520798
   PubMed Web of Science ®Google Scholar
• Tan S, Wang R, Ward MM. Syndesmophyte Growth in Ankylosing Spondylitis. Curr Opin Rheumatol. 2015;27(4):326–332. doi:10.1097/BOR.000000000000017926002023
   PubMed Web of Science ®Google Scholar
• Landewé R, Dougados M, Mielants H, van der Tempel H, van der Heijde D. Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine. Ann Rheum Dis. 2009;68(6):863–867. doi:10.1136/ard.2008.09179318628283
   PubMed Web of Science ®Google Scholar
• Zangi HA, Ndosi M, Adams J, et al. EULAR recommendations for patient education for people with inflammatory arthritis. Ann Rheum Dis. 2015;74(6):954–962. doi:10.1136/annrheumdis-2014-20680725735643
   PubMed Web of Science ®Google Scholar
• Sudre A, Figuereido IT, Lukas C, Combe B, Morel J. On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. Joint Bone Spine. 2012;79(1):99–100. doi:10.1016/j.jbspin.2011.06.00521852173
   PubMed Web of Science ®Google Scholar
• Candelas G, Villaverde V, García S, Guerra M, León MJ, Cañete JD. Benefit of health education by a training nurse in patients with axial and/or peripheral psoriatic arthritis: a systematic literature review. Rheumatol Int. 2016;36(11):1493–1506. doi:10.1007/s00296-016-3549-527544392
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO report on the global tobacco epidemic, 2017 Country profile: Kuwait Available from: http://www.who.int/tobacco/surveillance/policy/country_profile/kwt.pdf. Accessed 7 2018.
   Google Scholar
• Kaut IK, Abourazzak FE, Jamila E, Sènami FA, Diketa D, Taoufik H. Axial spondyloarthritis and cigarette smoking. Open Rheumatol J. 2017;11(1):53–61. doi:10.2174/187431290171101005328659998
   PubMedGoogle Scholar
• Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondyloarthritis. Arthritis Rheum. 2012;64:1388–1398. doi:10.1002/art.3346522127957
   PubMed Web of Science ®Google Scholar
• Ramiro S, Landewé R, van Tubergen A, et al. Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open. 2015;1(1):e000153. doi:10.1136/rmdopen-2015-00015326535153
   PubMedGoogle Scholar
• Chung HY, Machado P, van der Heijde D, D’Agostino MA, Dougados M. Smokers in early axial spondyloarthritis have earlier disease onset, more disease activity, inflammation and damage, and poorer function and health-related quality of life: results from the DESIR cohort. Ann Rheum Dis. 2012;71(6):809–816. doi:10.1136/annrheumdis-2011-20018021989541
   PubMed Web of Science ®Google Scholar
• Romanowski MW, Špiritović M, Rutkowski R, Dudek A, Samborski W, Straburzyńska-Lupa A. Comparison of deep tissue massage and therapeutic massage for lower back pain, disease activity, and functional capacity of ankylosing spondylitis patients: a randomized clinical pilot study. Evid Based Complementary Alternat Med. 2017;9894128.
   Web of Science ®Google Scholar
• Millner JR, Barron JS, Beinke KM, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arth Rheum. 2016;45:411–427. doi:10.1016/j.semarthrit.2015.08.00326493464
   PubMed Web of Science ®Google Scholar
• Chunco R. The effects of massage on pain, stiffness, and fatigue levels associated with ankylosing spondylitis: a case study. Int J Ther Massage Bodywork. 2011;4:12–17.21589691
   PubMedGoogle Scholar
• Baraliakos X, Kiltz U, Peters S, et al. Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis. Rheumatology (Oxford). 2017;56(1):95–102. doi:10.1093/rheumatology/kew36727997346
   PubMed Web of Science ®Google Scholar
• Wanders A, Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–1765. doi:10.1002/art.2105415934081
   PubMed Web of Science ®Google Scholar
• Kroon F, Landewé R, Dougados M, van der Heijde D. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis. 2012;71:1623–1629. doi:10.1136/annrheumdis-2012-20137022532639
   PubMed Web of Science ®Google Scholar
• Borer JS, Simon LS. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance. Arthritis Res Ther. 2005;7:14–22. doi:10.1186/ar1794
   PubMed Web of Science ®Google Scholar
• Rice JB, White AG, Scarpati LM, Wan G, Nelson WW. Long-term systemic corticosteroid exposure: a systematic literature review. Clin Ther. 2017;39(11):2216–2229. doi:10.1016/j.clinthera.2017.09.01129055500
   PubMed Web of Science ®Google Scholar
• Haibel H, Fendler C, Listing J, Callhoff J, Braun J, Sieper J. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis. 2014;73(1):243–246. doi:10.1136/annrheumdis-2012-20305523625982
   PubMed Web of Science ®Google Scholar
• Fraser AD, van Kuijk AWR, Westhovens R, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859–864. doi:10.1136/ard.2004.02446315528283
   PubMed Web of Science ®Google Scholar
• Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75:499–510. doi:10.1136/annrheumdis-2015-20833726644232
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther. 2009;11(4):R127. doi:10.1186/ar279419703304
   PubMed Web of Science ®Google Scholar
• Baraliakos X, Listing J, Fritz C, et al. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years–early clinical response predicts long-term outcome. Rheumatology (Oxford). 2011;50:1690–1699. doi:10.1093/rheumatology/ker19421672969
   PubMed Web of Science ®Google Scholar
• Sepriano A, Regel A, van der Heijde D, et al. Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. RMD Open. 2017;3(1):e000396. doi:10.1136/rmdopen-2016-00039628176964
   PubMed Web of Science ®Google Scholar
• Veale DJ, McGonagle D, McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019;58(2):197–205. doi:10.1093/rheumatology/key07029618084
   PubMed Web of Science ®Google Scholar
• Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology. 2012;51(8):1378–1387. doi:10.1093/rheumatology/kes02622427410
   PubMed Web of Science ®Google Scholar
• Saougou I, Markatseli TE, Voulgari PV, Drosos AA. Maintained clinical response of infliximab treatment in ankylosing spondylitis: a 6-year long-term study. Joint Bone Spine. 2010;77(4):325–329. doi:10.1016/j.jbspin.2010.02.01420452801
   PubMed Web of Science ®Google Scholar
• Wu D, Guo -Y-Y, Xu -N-N, et al. Efficacy of anti–tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta–analysis. BMC Musculoskelet Disord. 2015;16(1):19. doi:10.1186/s12891-015-0489-225888248
   PubMed Web of Science ®Google Scholar
• Calvo-Río V, Blanco R, Santos-Gómez M, et al. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients. Semin Arthritis Rheum. 2016;46:95–101. doi:10.1016/j.semarthrit.2016.03.00227060872
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007;57:639–647. doi:10.1002/art.2266917471540
   PubMed Web of Science ®Google Scholar
• Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Monoclonal antibodies inhibiting IL-12, −23, and −17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017;13(10):2247–2259. doi:10.1080/21645515.2017.135649828825875
   PubMed Web of Science ®Google Scholar
• Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis–results of two Phase 3 trials. N Engl J Med. 2014;371:326–338. doi:10.1056/NEJMoa131425825007392
   PubMed Web of Science ®Google Scholar
• Thibodaux RJ, Triche MW, Espinoza LR. Ustekinumab for the treatment of psoriasis and psoriatic arthritis: a drug evaluation and literature review. Expert Opin Biol Ther. 2018;18(7):821–827. doi:10.1080/14712598.2018.149254529949399
   PubMed Web of Science ®Google Scholar
• Kehl AS, Corr M, Weisman WH. Enthesitis. New insights into pathogenesis, diagnostic modalities, and treatment. Arthritis Rheumatol. 2016;68:312–322. doi:10.1002/art.3945826473401
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Braun J, Deodhar A, et al. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing (GO-RAISE). Rheumatology. 2013;52:321–325. doi:10.1093/rheumatology/kes25123024015
   PubMed Web of Science ®Google Scholar
• Rudwaleit M, Claudepierre P, Kron M, Kary S, Wong R, Kupper H. Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis. Arthritis Res Ther. 2010;12(2):R43. doi:10.1186/ar295320230622
   PubMed Web of Science ®Google Scholar
• Feuchtenberger M, Schäfer A, Nigg AP, Kraus MR. Hepatitis B serology in patients with rheumatic diseases. Open Rheumatol J. 2016;10(1):39–48. doi:10.2174/187431290161001003927708728
   PubMedGoogle Scholar
• Xie X, Li F, Chen JW, Wang J. Risk of tuberculosis infection in anti-TNF-a biological therapy: from bench to bedside. J Microbiol Immunol Infect. 2014;47:268–274. doi:10.1016/j.jmii.2013.03.00523727394
   PubMedGoogle Scholar
• Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol. 2016;21:10274–10289. doi:10.3748/wjg.v21.i36.10274
   Web of Science ®Google Scholar
• World Health Organization. Guidelines on the management of latent tuberculosis infection. Available from: http://www.who.int/tb/publications/ltbi_document_page/en/. Accessed 291 2019.
   Google Scholar
• World Health Organization. Chest radiography in tuberculosis detection. Available from: https://www.who.int/tb/publications/chest-radiography/en/. Accessed 291 2019.
   Google Scholar
• Ledingham J, Gullick N, Irving K, et al. BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. Rheumatology. 2017;56(6):865–868. doi:10.1093/rheumatology/kew47928339817
   PubMed Web of Science ®Google Scholar
• Ossum AM, Palm Ø, Lunder AK, et al. ankylosing spondylitis and axial spondyloarthritis in patients with long-term inflammatory bowel disease: results from 20 years of follow-up in the IBSEN study. J Crohns Colitis. 2018;12(1):96–104. doi:10.1093/ecco-jcc/jjx12628961700
   PubMed Web of Science ®Google Scholar
• Mitulescu TC, Popescu C, Naie A, et al. Acute anterior uveitis and other extra-articular manifestations of spondyloarthritis. J Med Life. 2015;8(3):319–325.
   Google Scholar
• Ogdie A, Schwartzman S, Husni ME. Recognizing and managing comorbidities in psoriatic arthritis. Curr Opin Rheumatol. 2015;27(2):118–126. doi:10.1097/BOR.000000000000015225603040
   PubMed Web of Science ®Google Scholar
• Lee S, Mendelsohn A, Sarnes E. The burden of psoriatic arthritis: a literature review from a global health systems perspective. P T. 2010;35:680–689.21197266
   PubMedGoogle Scholar
• Winthrop KL, Strand V, van der Heijde DM, et al. The unmet need in rheumatology: reports from the targeted therapies meeting 2016. Clin Exp Rheumatol. 2016;4(Suppl 98):69–76.
   Google Scholar
• Gelfand J. Metabolic syndrome in patients with psoriatic disease. J Rheumatol Suppl. 2012;89:24–28. doi:10.3899/jrheum.12023722751586
   PubMedGoogle Scholar
• Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147:1031–1039. doi:10.1001/archdermatol.2011.11921576552
   PubMedGoogle Scholar
• Gelfand JM, Dommasch ED, Shin DB, et al. The risk of stroke in patients with psoriasis. J Invest Dermatol. 2009;129(10):2411–2418. doi:10.1038/jid.2009.11219458634
   PubMed Web of Science ®Google Scholar
• Ludwig RJ, Herzog C, Rostock A, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007;156(2):271–276. doi:10.1111/j.1365-2133.2006.07562.x17223866
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ang M, Su L, Tom BD, Schentag CT, Farewell VT. Cardiovascular morbidity in psoriatic arthritis. Ann Rheum Dis. 2009;68(7):1131–1135. doi:10.1136/ard.2008.09483918697777
   PubMed Web of Science ®Google Scholar
• Raychaudhuri SK, Chatterjee S, Nguyen C, Kaur M, Jialal I, Raychaudhuri SP. Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord. 2010;8(4):331–334. doi:10.1089/met.2009.012420367239
   PubMed Web of Science ®Google Scholar